, , ,
Avda Bio

Putting The Power Of Cell Therapy In Every Hospital

About this Event

CAR-T cell therapy represents a breakthrough in the treatment of many diseases, providing up to a 90% response rate for termly ill patients with cancers like leukemia and lymphoma. The problem is current centralized method of manufacturing CAR-T cells takes too long, is expensive, and can’t meet the demand.

Adva Biotechnology has shifted the production paradigm for producing CAR-T cells from a centralized and highly skilled labor-intensive model to a distributed model with the introduction of the Adva X3 platform. It allows for point-of-care manufacturing, which results in the availability of the treatment of personally-engineered cells in about a week instead of months, costs one-fifth of the current, and is scalable, ensuring the availability of disruptive, personalized Immune cell therapy for cancer patients worldwide.

The ADVA X3 is an all-in-one, benchtop system that performs the entire CAR-T process in one automated process in a standard hospital clean room. It is the only device that can produce several different therapy products and up to 20 billion cells in each batch and is so simple to use, a lab technician can operate it.

Watch this webinar with AdvaBio to learn how they’ve developed a revolutionary decentralized, automated and efficient manufacturing platform for advanced cell therapy in one benchtop system.

Video On Demand

– Recorded

April 9

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.